Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Nicoletta Colombo, Ursula Denison, Ignace Vergote, Jose M Del Campo, Petronella Ottevanger, Martin Heubner, Thomas Minarik, Emmanuel Sevin, Nikolaus de Gregorio, Mariusz Bidziński, Jacobus Pfisterer, Susanne Malander, Felix Hilpert, Mansoor Raza Mirza, Giovanni ScambiaWerner Meier, Maria O Nicoletto, Line Bjørge, Alain Lortholary, Martin Oliver Sailer, Michael Merger, Philipp Harter, AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium

Research output: Contribution to journalJournal articleResearchpeer-review

121 Citations (Scopus)
Original languageEnglish
JournalLancet Oncology
Volume17
Issue number1
Pages (from-to)78-89
Number of pages12
ISSN1470-2045
DOIs
Publication statusPublished - Jan 2016

Bibliographical note

Member of Study group

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Carcinoma
  • Cytoreduction Surgical Procedures
  • Diarrhea
  • Disease Progression
  • Disease-Free Survival
  • Double-Blind Method
  • Fallopian Tube Neoplasms
  • Female
  • Humans
  • Indoles
  • Intention to Treat Analysis
  • Middle Aged
  • Neoplasm Staging
  • Neutropenia
  • Ovarian Neoplasms
  • Paclitaxel
  • Peritoneal Neoplasms
  • Response Evaluation Criteria in Solid Tumors
  • Thrombocytopenia
  • Young Adult
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Cite this